Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Nov. 19, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 ... announced the addition of the  "The Global ... 2-D Nanomaterials "  report to their offering.  ... and graphene are the strongest, lightest and ... a performance-per-weight greater than any other material. ...
(Date:10/22/2014)... 21, 2014 The North American crystal ... North America with analysis and forecast of revenue. This ... is expected to reach $623.6 million by 2018, at ... Browse through the TOC of the North American crystal ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/22/2014)... Grace Century, a private equity consultancy ... the addition of Dr. Yousef “Josh” Siddiqui , ... Dr. Siddiqui will provide further healthcare expertise to its ... University College Medical School in the late ... 2001. With further certification as a General Practitioner (GP), ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Cleanup and rebuilding teams responding to the devastation across ... help from space. A series of crisis map products ... provided to aid damage assessment efforts following the activation ... , More than 60 people were killed and thousands ...
... Professor of Chemical Engineering at Vanderbilt, will receive ... Nanoscale Science and Engineering Forum Award at the ... outstanding contributions to the advancement of nanoscale science ... through scholarship, education or service. , Cummings is ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a ... product candidates for the treatment,of cancer and infectious ... executive officer, is scheduled to present at the ... p.m. Pacific Time (4:45,p.m. Eastern Time). The conference ...
Cached Biology Technology:Greeks get space-based help in wake of deadly fires 2Peter Cummings to receive the 2007 AIChE Nanoscale Science and Engineering Forum Award 2ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum 2
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... people seem to eat anything they want and never gain ... looking at fattening foods? You may be seeing things ... 2010 issue of Genetics ( http://www.genetics.org ), this ... found that genes interacting with diet, rather than diet alone, ...
... found that an enzyme in the bacteria that causes ... bacteria with energy. Because the enzyme is not found ... insights into how drugs might be created to kill ... a Rensselaer associate professor of biology, led a team ...
... July 28, 2010 A yearlong beach study led ... that swimmers at sub-tropical beaches face an increased risk ... illness that beachgoers face when exposed to recreational marine ... pollution or contamination. B.E.A.C.H.E.S. (Beach Environmental ...
Cached Biology News:Why fad diets work well for some, but not others 2Rensselaer professor uncovers mysterious workings of cholera bacteria 2Rensselaer professor uncovers mysterious workings of cholera bacteria 3Study suggests swimmers at sub-tropical beaches show increased risk of illness 2
... Grace's Insect Medium is formuatled ... lines including Sf9 and Sf21 cells. ... for transfectioin because it does not ... can interfere with transfection. Grace's Insect ...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
...
...
Biology Products: